Vira Shield 6 + VL5 HB (Canada)

Company: Elanco

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine

Killed Virus

Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin

For Use in Animals Only

Vira Shield 6 + VL5 HB Indications

For use in healthy breeding cattle, including pregnant cows and heifers, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis (IBR), bovine virus diarrhea (BVD Type 1 and BVD Type 2), parainfluenza Type 3 (PI₃), and bovine respiratory syncytial (BRSV) viruses and Campylobacter fetus, Leptospira canicola, grippotyphosa, hardjo-bovis, icterohaemorrhagiae, and pomona. For use in calves vaccinated at four weeks of age, or older, as an aid in the prevention of hardjo-bovis kidney colonization, and as an aid in preventing urinary shedding and reproductive tract infection for 12 months. Produced from non-cytopathic (BVD Type 1 and BVD Type 2) and cytopathic (BVD Type 1) isolates. Vaccinated animals subsequently exposed to L. borgpetersenii serovar hardjo (type hardjo-bovis) have been shown to clear renal infections within 8 weeks of exposure.

ADJUVANT: Xtend™ SP

Directions For Use

Shake well before using. Administer 5 mL subcutaneously 2-4 weeks prior to breeding. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck. Revaccinate with Vira Shield 6 + L5HB in 4-5 weeks. Revaccinate annually or as recommended by your veterinarian.

Precautions

Store out of direct sunlight at 2°-8°C (35°-46°F). DO NOT FREEZE. Use entire contents when first opened. Do not mix with other products, except as specified on the label. In case of human exposure, contact a physician. Do not vaccinate within 60 days prior to slaughter. Transient swelling may occur at the site of injection. Milk reduction and transient depression may be observed in lactating dairy cows for 3-6 days following vaccination. Anaphylactic reactions may occur. Symptomatic treatment: Epinephrine. Contains amphotericin B, gentamicin, and thimerosal as preservatives.

Manufactured by Elanco US Inc., Fort Dodge, IA, USA.

USDA Vet. Biologics Est. Lic. No. 196.

For Elanco Canada Limited, Mississauga, Ontario, Canada L5N 0C9; 1-800-265-5475.

Vira Shield, Xtend, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2022 Elanco or its affiliates.

CPN: 1231108.4